

Cristiana Ercolani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7243918/publications.pdf>

Version: 2024-02-01

29
papers

990
citations

516710

16
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

2531
citing authors

#	ARTICLE	IF	CITATIONS
1	Not enough can be enough: feasibility of the Idylla<i>EGFR</i> mutation test when reuse of stained tissue slides is the only option available. <i>Journal of Clinical Pathology</i> , 2022, 75, 844-850.	2.0	2
2	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , 2021, 20, 151.	19.2	9
3	Pyruvium Pamoate Induces Death of Triple-Negative Breast Cancer Stemâ€“Like Cells and Reduces Metastases through Effects on Lipid Anabolism. <i>Cancer Research</i> , 2020, 80, 4087-4102.	0.9	36
4	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e761-e770.	2.4	4
5	Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 103.	8.6	5
6	microRNA-378a-5p is a novel positive regulator of melanoma progression. <i>Oncogenesis</i> , 2020, 9, 22.	4.9	30
7	Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. , 2020, 8, e000489.		30
8	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	2
9	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 278.	8.6	19
10	Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 95.	8.6	25
11	Body mass index modifies the relationship between Î³-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	2.6	12
12	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	3.4	22
13	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 2246-2252.	4.1	9
14	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017, 7, 8078.	3.3	14
15	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 143.	8.6	4
16	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016, 6, 35121.	3.3	6
17	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 62.	8.6	24
18	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016, 7, 43188-43198.	1.8	35

#	ARTICLE	IF	CITATIONS
19	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	1.8	14
20	Gene Status in <i>HER2</i> Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method. <i>Oncologist</i> , 2014, 19, 1118-1126.	3.7	37
21	miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1. <i>Cancer Research</i> , 2014, 74, 4145-4156.	0.9	108
22	Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensitivity after radioembolization with yttrium-90 resin microspheres. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 13.	8.6	16
23	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , 2013, 133, 1259-1265.	5.1	154
24	External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 58.	8.6	9
25	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 699-706.	1.8	16
26	Overexpression of activated phospholipase C β 1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2013, 132, 1022-1031.	5.1	41
27	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. <i>Cell Death and Disease</i> , 2012, 3, e423-e423.	6.3	160
28	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. <i>Clinical Cancer Research</i> , 2011, 17, 2055-2064.	7.0	92
29	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. <i>Journal of Translational Medicine</i> , 2011, 9, 184.	4.4	55